AI-generated summary
The authors systematically reviewed 18 randomized controlled trials of low-level laser therapy for maxillofacial neuropathies, reporting pain reduction, faster sensory recovery and shorter healing times compared with controls. Mild adverse events were reported in under 5% of cases. The authors note variable laser dosimetry and small sample sizes across studies.
- Participants
- 1,220
- Studies included
- 18
- Who or what was studied
- Patients with maxillofacial neuropathies, including paresthesia, neuralgia or facial paralysis
- Limits stated in the abstract
- The authors note variability in laser dosimetry and small sample sizes across the included studies, and call for standardized protocols and multicenter trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Systematic review, Visual analogue scale, Dosimetry, Collagen. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.